CAMELOT FANTASIES

CAMELOT FANTASIES => Stocks Universe => Topic started by: Clay Death on March 28, 2017, 07:35:47 am

Title: Re: CGIX
Post by: Clay Death on April 26, 2017, 07:07:36 pm

Quote from: Swish on April 26, 2017, 05:41:35 pm

This looks like a great company, went up again today.

I agree.

they are producing record revenues also.



shorts have been after it but they will get burned in my estimation.


especially if it keeps rising.

Title: Re: CGIX
Post by: Swish on April 26, 2017, 05:41:35 pm

This looks like a great company, went up again today.

Title: Re: CGIX
Post by: Clay Death on April 03, 2017, 02:28:09 pm

https://finance.yahoo.com/news/cancer-genetics-inc-mendel-ai-110000688.html

Title: Re: CGIX
Post by: Clay Death on March 28, 2017, 06:20:11 pm

Cancer Genetics, Inc. to Present at The MicroCap Conference on April 4th at 08:00 AM in New York City
4:10 pm ET March 28, 2017 (Globe Newswire)



Cancer Genetics, Inc. (Nasdaq:CGIX) a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announced today that Company CEO and President, Panna Sharma, will be presenting an overview of the Company and strategy at 8 AM Eastern on April 4th at the MicroCap Conference.
A webcast of the presentation will be available at http://wsw.com/webcast/microcapconf3/cgix.
CONFERENCE OVERVIEW AND STRUCTURE
The MicroCap Conference is an exclusive event for investors who specialize in small and microcap stocks. It is an opportunity to be introduced to and speak with management at some of the most attractive small companies, learn from various expert panels, and mingle with other investors. The MicroCap Conference will take place in New York City at the Essex House on April 4th. The day will be jam-packed with company presentations, one-on-one meetings, good food, and plenty of time to network with other investors over drinks at the reception.
ABOUT CANCER GENETICS:
Cancer Genetics, Inc. is an emerging leader in enabling precision medicine for oncology through the use of molecular markers and information. CGI is developing a global footprint with locations in the US, India and China. We have established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.
The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State.

Title: Re: CGIX
Post by: Clay Death on March 28, 2017, 08:13:33 am

http://finance.yahoo.com/news/cancer-genetics-inc-receive-1-131252091.html

Title: Re: CGIX
Post by: Clay Death on March 28, 2017, 07:37:30 am

https://finance.yahoo.com/news/cancer-genetics-inc-announces-record-113000373.html

Title: Re: CGIX
Post by: Clay Death on March 28, 2017, 07:36:24 am

https://finance.yahoo.com/news/cancer-genetics-therapix-biosciences-financial-133000960.html

Title: CGIX
Post by: Clay Death on March 28, 2017, 07:35:47 am

https://finance.yahoo.com/m/eb36da92-42ef-3061-84bf-78e2ff1a2475/etfs-with-exposure-to-cancer.html